Key Concept

Key Evidence: The US CDC estimates that antibiotic resistant pneumococcal infections in the US add $96 million to the costs of treatment each year.

Centers for Disease Control and Prevention 2013. Antibiotic resistance threats in the United States, 2013 (Report).
View Publication >

Key Evidence: The costs and health effects of treating typhoid might soon increase dramatically, since the bacteria that causes typhoid is becoming increasingly resistant to the most effective oral antimicrobial drugs, thus requiring treatment with more expensive intravenous antibiotics which may result in more frequent hospitalizations for suspected typhoid cases.

Andrews JA, Baker S, Marks F et al. 2019. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infectious Disease. 19(1).
View Publication >